Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial
UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will
✦ Editorial Summary
Bimzelx has demonstrated superiority over Skyrizi in a head-to-head trial for psoriatic arthritis, marking the first time an approved biologic has outperformed an IL-23 blocker in this condition. This achievement may have significant implications for the treatment of psoriatic arthritis. However, analysts remain uncertain about the commercial impact of these results.
WOKHEI The excerpt above is sourced from the original publication. WokHei does not add editorial bias. Click the link below to read the full article at the source.
Discussion
Join the discussion
Sign in for a verified badge and your comments appear instantly. Or post anonymously — anonymous comments are held briefly for moderation.
More in Health & Fitness
View all →Health & Fitness
genomoncology/biomcp
github.com·AI 5/10
Health & Fitness
Iran’s black rain could expose millions to toxic chemicals after massive oil fires darkened skies over Tehran. Health experts say rainfall can pull soot, petroleum residues and carcinogenic particles from smoke plumes. Doctors warn of respiratory illness and cancer risk.
rathbiotaclan.com
Health & Fitness
Algorithm allows paramedics to predict brain damage risk after cardiac arrest
medicalxpress.com
Health & Fitness
Fascinating story: Tech Entrepreneur in Australia, using ChatGPT, AlphaFold, and a custom made mRNA vaccine, treats his dog's cancer. With the help of researchers (who all seem so excited) he was able to significantly reduce tumour size just weeks after the first injection
reddit.com·AI 5/10
WokHei Digest
Workflow insights, delivered
Curated tips, tools, and tutorials for builders — twice a month, no spam.